desmoidtumors

Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.

Dr. Aaron Weiss is a board certified pediatric hematologist/oncologist practicing in Maine. He is an associate professor and the Division Director of Pediatric Hematology-Oncology at Tufts University School of Medicine and he holds the Sam L Cohen Medical Director Endowed Chair at Maine Children’s Cancer Program. As part of Children's Oncology Group he is the Vice-Chair of the Soft Tissue Sarcoma Committee, and the Associate Vice-Chair of the Clinical Trials, AYA Oncology Discipline Committee. He is an expert in Desmoid tumors and he is the chair of the Desmoid Tumor Research Foundation Medical Advisory Board.

In this episode we discuss:

- What led Dr. Weiss into his expertise of soft tissue sarcomas and specifically Desmoid tumors

- Is a Desmoid tumor and cancer and why does the cancer classification matter?

- Where do Desmoid tumors occur and the profound affect on quality of life for patients

- Should the clinical trial endpoints for Desmoid tumors change?

- All areas of Desmoid tumor treatment including: - Localized treatment such as high intensity ultrasound - Systemic treatment from chemotherapy to targeted therapies - The importance of active surveillance as a treatment option - Why some treatments have fallen out of favor and what is on the horizon

music: Rospigg

photo: Felix-Mittermeier